[1] Kidney Disease Improving Global Outcomes. Definition and classification of AKI[J]. Kidney Int, 2012,2(s1):19-36. [2] Ali T,Khan I,Simpson W, et a1. Incidence and outcomes in acute kidney injury: a comprehensive population-based study[J]. J Am Soc Nephrol, 2007,18(4):1292-1298. [3] Lewington A J, Cerda J, Mehta R L. Raising awareness of acute kidney injury:a global perspective of a silent killer[J]. Kidney Int, 2013,84(3):457-467. [4] Luyckx V A, Naicker S. Acute kidney injury associated with the use of traditional medicines[J]. Nat Clin Pract Nephrol, 2008,4(12):664-671. [5] Pannu N, Nadim M K. An overview of drug-induced acute kidney injury[J]. Cri Care Med, 2008,36(4Suppl):S216-223. [6] 王俊锋. 2007-2014年我国药物性急性肾损伤文献调查与分析[J]. 临床误诊误治, 2014,27(10):54-57. [7] 张彤, 梅长林. 急性肾衰竭100例临床分析[J]. 中华肾脏病杂志, 2005,21(12):732-735. [8] 陈伟, 刘华锋. 抗菌药物相关急性肾损伤的新认识[J]. 临床合理用药, 2010,3(1):124-126. [9] 张媛媛, 刘华锋. 非甾体类抗炎药相关急性肾衰竭新进展[J]. 医学综述, 2010,16(22):3450-3452. [10] 李中东, 王大猷. COX-2抑制剂与急性肾衰[J]. 药物不良反应杂志, 2001,3(1):56. [11] 郭晨雯, 范春, 王京鹰. 环氧化酶II 选择性抑制剂的临床应用及存在的问题[J]. 中国医院药学杂志, 2003,23(9):559-560. [12] Musu M, Finco G, Antonucci R, et al. Acute nephrotoxicity of NSAID from the foetus to the adult[J]. Eur Rev Med Pharmacol Sci, 2011,15(12):1461-1472. [13] Bentley M L, Corwin H L, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies[J]. Cri Care Med, 2010,38 (s6):S169-S174. [14] Nash K, Hafeez A, Hou S. Hospital-aquired renal insufficiency[J]. Am J Kidney Dis, 2002, 39(5):930-936. [15] 韩雅玲. 重视对比剂诱导的急性肾损伤[J]. 解放军医学杂志, 2014,39(4):255-258. [16] Rudnick M R, Goldfarb S, Tumlin J. Contrast-induced nephropathy: is the picture any clearer[J]. Clin J Am Soc Nephrol, 2008,3(1):261-262. [17] Schetz M, Dasta J, Goldstein S, et al. Drug-induced acute kidney injury[J]. Curr Opin Crit Care, 2005,11(6):555-565. [18] Ruffenach S J, Siskind M S, Lien Y H. Acute interstitial nephritis due to omeprazole[J]. Am J Med, 1992,93(4):472-473. [19] Torpey N, Barker T, Ross C. Drug-induced tubule-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit[J].Nephrol Dial Transplant, 2004,19(6):1441-1446. [20] Geevasinga N, Coleman P L, Roger S D. Rabeprazole-induced acute interstitial nephritis[J]. Nephrology (Carlton), 2005,10(1):7-9. [21] Simpson I J, Marshall M R, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases[J]. Nephrology(Carlton), 2006,11(5):381-385. [22] Klepser D G, Collier D S, Cochran G L. Proton pump inhibitors and acute kidney injury: a nested case-control study[J]. BMC Nephrol, 2013,14:150. [23] Muriithi A K, Leung N, Valeri A M, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series[J]. Am J Kidney Dis, 2014,64(4):558-566. [24] 程骏章, 姜鸿. 奥美拉唑致过敏性紫癜性肾炎1例[J]. 中国药师, 2007,10(5):477. [25] 张晓东, 方敬爱, 武明虎. 奥美拉唑导致间质性肾炎的临床分析[J]. 中国中西医结合肾病杂志, 2006,7(9):543. [26] Muriithi A K, Leung N, Valeri A M, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly[J/OL]. Kidney Int, 2015,87 (2):458-464. [27] Brewster U C, Perazella M A. Proton pump inhibitors and the kidney: critical review[J]. Clin Nephrol, 2007,68(2):65-72. [28] Perazella M A, Markowitz G S. Drug-induced acute interstitial nephritis[J]. Nat Rev Nephrol, 2010,6(8):461-470. [29] Brewster U C, Perazella M A. Acute kidney injury following proton pump inhibitor therapy[J]. Kidney Int, 2007,71(6):589-593. [30] Geevasinga N, Coleman P L, Webster A C, et al. Proton pump inhibitors and acute interstitial nephritis[J]. Clin Gastroenterol Hepatol, 2006,4(5):597-604. [31] Blank M L, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use[J]. Kidney Int, 2014,86(4):837-844. [32] Fisher A A, Le Couteur D G. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists [J]. Drug Saf, 2001,24(1):39-57. [33] Gaughan W J, Sheth V R, Francos G C, et al. Ranitidine-induced acute interstitial nephritis with epithelial cell foot process fusion[J]. Am J Kidney Dis, 1993,22 (2):337-340. [34] Neelakantappa K, Gallo G R, Lowenstein J. Ranitidine-associated interstitial nephritis and Fanconi syndrome[J]. Am J Kidney Dis, 1993,22(2):333-336. [35] Russo A, Mirani A, Perlman J, et al. Enalapril-induced acute kidney injury in neonates[J]. J Neonatal Perinatal Med, 2013,6(2):179-181. [36] Hanevold C D. Acute renal failure during lisinopril and losartan therapy for proteinuria[J]. Pharmacotherapy, 2006,26(9):1348-1351. [37] Phillips C O, Kashani A, Ko D K, et a1. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction[J]. Arch Intern Med, 2007,167(18):1930-1936. [38] Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin- (1-7)-Mas receptor axis[J]. Hypertens Res, 2009,32(7):533-536. [39] 谷松磊, 白海涛. 血管紧张素转换酶抑制剂和血管紧张素II 1型受体拮抗剂抑制血管紧张素II促增殖在急性肾损伤发生发展中的作用[J]. 临床内科杂志, 2013,30(6):431-432. [40] Scherpbier N D, de Grauw W J, Wetzels J F, et al. Acute renal failure due to RAAS-inhibitors combined with dehydration[J]. Ned Tijdschr Geneeskd, 2010,154:A1548. [41] Townsend R R, Cohen D L. Use of diuretics with ACE inhibitors or angiotensin receptor blockers and NSAIDs increases the risk of acute kidney injury[J]. Evid Based Med, 2013,18(6):232-233. [42] 何兰, 周巧玲. Netrin-1在急性肾损伤中的作用[J]. 中国医师杂志, 2011,2(z2):200-202. [43] Cruz C S, Cruz L S, Silva G R, et al. Incidence and predictors of development of acute renal failure related to treatment of congestive heart failure with ACE inhibitors[J]. Nephron Clin Pract, 2007,105(2):77-83. [44] Ejaz A A, Fitzpatrick P M, Haley W E, et al. Amlodipine besylate induced acute interstitial nephritis[J]. Nephron, 2000,85(4):354-356. [45] Naha K, Suryanarayana J, Aziz R A, et al. Amlodipine poisoning revisited: acidosis, acute kidney injury and acute respiratory distress syndrome[J]. Indian J Crit Care Med, 2014,18(7):467-469. [46] Kute V B, Shah P R, Goplani K R, et al. Successful treatment of refractory hypotension, noncardiogenic pulmonary edema and acute kidney injury after an overdose of amlodipine[J]. Indian J Crit Care Med, 2011,15(3):182-184. [47] Gandhi S, Fleet J L, Bailey D G, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury[J]. JAMA. 2013,310(23):2544-2553. [48] Markowitz G S, Perazella M A. Acute phosphate nephropathy[J]. Kidney Int, 2009,76(10):1027-1034. [49] Ori Y, Rozen-Zvi B, Chagnac A, et al. Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience [J]. Arch Intern Med, 2012,172(3):263-265. [50] FDA. Oral Sodium Phosphate (OSP) Products for Bowel Cleansing[EB/OL].(2006-03)[2014-11-25].http://www.fda.gov/Drugs/Drug-Safety/PostmarketDrugSafetyInformationforPatientsandProviders%20/ucm161565.htm. [51] FDA. Oral Sodium Phosphate (OSP) Products for Bowel Cleansing (marketed as Visicol and OsmoPrep, and oral sodium phosphate products available without aprescription)[EB/OL].(2008-11-12)[2014-11-25]. http://www.fda.gov/Drugs/DrugSafety/Post marketDrugSafetyInformationforPatientsandProviders/ucm126084.htm. [52] FDA. FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation[EB/OL].(2014-08-01)[2014-11-25].http://www.fda.gov/Drugs/DrugSafety/ucm380757.htm. [53] Markowitz G S, Nasr S H, Klein P, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing[J]. Hum Pathol, 2004,35 (6):675-684. [54] Gumurdulu Y, Serin E, Ozer B, et al. Age as a predictor of hyperphosphatemia after oral phosphosoda administration for colon preparation[J]. J Gastroenterol Hepatol, 2004,19(1):68-72. [55] Brunelli S M, Lewis J D, Gupta M, et al. Risk of kidney injury following oral phosphosoda bowel preparations[J]. J Am Soc Nephrol, 2007,18(2):3199-3205. [56] Barclay R L. Safety, efficacy, and patient tolerance of a three-dose regimen of orally administered aqueous sodium phosphate for colonic cleansing before colonoscopy[J]. Gastrointest Endosc, 2004, 60(4):527-533. [57] Russmann S, Lamerato L, Motsko S P, et al. Risk of further decline in renal function after the use of oral sodium phosphate or polyethy-lene glycol in patients with a preexisting glomerular filtration rate below 60 ml/min[J]. Am J Gastroenterol, 2008,103(11):2707-2716. [58] Khurana A, McLean L, Atkinson S, et al. The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy[J]. Arch Intern Med, 2008,168(6):593-597. [59] Eremina V, Jefferson J A, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy[J]. N Engl J Med, 2008,358(11):1129-1136. [60] Muallem S, Moe O W. When EGF is offside, magnesium is wasted[J]. J Clin Invest, 2007,117 (8):2086-2089. [61] Perazella M A, Markowitz G S. Bisphosphonate nephrotoxicity[J]. Kidney Int, 2008,74(11):1385-1393. [62] 张玉萌, 栗晓东, 刘萍,等. 穿心莲制剂引起急性肾毒性的文献回顾性分析[J]. 中国药物应用与监测, 2010,7(6):360-362. [63] 易扬, 马骏, 王汉清,等. 白蔹致急性肾损伤一例[J]. 中华肾脏病杂志, 2014,30(3):235-236. [64] 解倩, 陆敏, 申洪波,等. 中汤药相关性急性肾损伤患者32例临床分析[J]. 中国老年学杂志, 2011,31(24):4804-4805. [65] 段永红. 致肾损害中药品种文献分析[J]. 海峡药学, 2014,26 (4):138-139. [66] 堪贻璞. 中草药引起的肾损害[J]. 中华肾脏病杂志, 2005,21(3):121-122. [67] 尹世强, 邹爱英, 刘秀书,等. 中药导致肾损害相关性分析及预防[J]. 天津药学, 2013,25(4):55-57. |